R Visit www.retro.bio →
Founded2021
HQRedwood City, California
RoleLongevity drug developer running parallel programs in autophagy, cell replacement, and tissue reprogramming; lead candidate RTR242 is in a first-in-human Alzheimer's trial.
The lenses
Scored on its own merits — not rolled up from the finds we publish.
Novelty 3
Impact · breadth 3
Impact · depth 3
Actionable 2
Substance 3
Hype 3
Related concepts
Appears in finds
Top 5 · Retro Biosciences
Lens
Window
Theme
Overall = breadth + depth + substance + ½·novelty + freshness (a small boost that halves each week)
01 
02 
See the full feed → paperLongevity & Health
The model rewrote a third of the protein
OpenAI's protein language model redesigned two of the factors that turn an adult cell back into a stem cell — and the winning variants differ from the natural proteins by more than a hundred amino acids.
Overall▅▃▄▂▄▃medium · first-partyMentat
paperLongevity & Health
The cleanup crew, restarted
Sam Altman's longevity venture put a number on itself — a $1.8B valuation — but its lead drug is unglamorous: an oral pill that re-acidifies aging cells so they can resume their own garbage disposal.
Overall▃▃▃▂▃▄medium · first-partyRetro Biosciences
No finds in this window — widen it to see more.
How this connects
Tap a node to open it
Retro BiosciencesLongevity & HealthBiotech & Synthetic BiologyHuman EnhancementThe model rewrote a third of the proteinThe cleanup crew, restartedAutophagyEpigenetic reprogrammingGene therapyArtificial IntelligenceDemis HassabisJennifer DoudnaEli LillyElon MuskAlphabetOpenAIJ. Craig Venter InstituteThe edit that lowers cholesterolInsilico MedicineVERVE-102Verve TherapeuticsNEO